Trump's remarks are pressing the shares of Asian pharmaceutical businesses

The shares of Asian pharmaceutical businesses fell after US President Donald Trump announced his intention to issue an executive order to lower the prices of medicines prescribed in the United States to match the prices approved in other countries. The share of the Japanese company “Chogai Pharmaceutical Industries” fell by 7.2% at the beginning of the Tokyo session, in the biggest drop in a month, while the “Dayyishi Sancio” and “Takked” lost about 5%. In South Korea, the shares of “SK Biovarmasotias”, “Celticon” and “Samsung biologists” have all dropped by more than 3%. These declines came after Trump announced on social media that he intended to sign an executive order on Monday to sign Nine in the morning Washington to lower prices of prescribed medicine, after reports on the plan that appeared last week. The sector is under the pressure of Trump the pressure of this announcement on the shares of pharmaceutical businesses, amid fear that this policy will negatively affect its profits if it is forced to lower its prices in the US market. “The extent to which Trump’s plan is impossible to implement, but the advertisement itself is negative for the pharmaceutical sector,” said Hedimaru Yamguchi, an analyst of the healthcare sector at City Group Global Markets in Japan. He added that companies that rely on the US market as a major source of income, such as “Takada”, “Astilas Pharma” and “Otusuka Holdings”, will be the most vulnerable to influence. The shares of “Astilas” and “Ottisuka” also registered a decline on Monday.